All eyes on Pfizer as palbociclib prepares to take the stage

Last month, Pfizer ($PFE) said it was "delighted" with the Phase II results of palbociclib, its in-development breast cancer drug, fanning expectations that the drugmaker might make its case to the FDA before embarking on a late-stage study. Now, with Pfizer expected to get into specifics on the breakthrough-designated therapy at this weekend's American Association for Cancer Research meeting in San Diego, analysts will be all ears as the company sheds light on its would-be blockbuster. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.